CORRESP 1 filename1.htm


TRINITY BIOTECH PLC
 
March 26, 2025
 
VIA EDGAR
 
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549

Attention:
Daniel Crawford

Re: Trinity Biotech plc
Registration Statement on Form F-3
File No. 333- 286020

To Mr. Crawford:
 
The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered by the above-referenced Registration Statement, hereby respectfully requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:00 p.m. Eastern Time on Friday, March 28, 2025, or as soon thereafter as possible.
 
Please contact Steven Glusband (212-238-8605, glusband@clm.com) or Mary Brown (212-238-8765, mbrown@clm.com) of Carter Ledyard & Milburn LLP with any questions you may have concerning this request.
 
 
Very truly yours,

/s/ Louise Tallon
Louise Tallon
Chief Financial Officer